Artiva Biotherapeutics (ARTV) Other Accumulated Expenses (2023 - 2026)

Artiva Biotherapeutics (ARTV) has 4 years of Other Accumulated Expenses data on file, last reported at $1.1 million in Q1 2026.

• Other Accumulated Expenses for Q1 2026 came in at $1.1 million, up 1445.21% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.1 million (up 1445.21% YoY), and the FY2025 annual result was $858000.0, up 10.85% from the prior year.
• Other Accumulated Expenses improved to $1.1 million in Q1 2026 per ARTV's latest filing, from $858000.0 in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $2.9 million in Q4 2023 and troughed at $73000.0 in Q1 2025.
• A 4-year average of $1.2 million and a median of $927500.0 in 2025 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2025 and 2026: Other Accumulated Expenses tumbled 80.07% in 2025, then surged 1445.21% in 2026.
• A 4-year view of Other Accumulated Expenses shows it stood at $2.9 million in 2023, then tumbled by 72.95% to $774000.0 in 2024, then gained by 10.85% to $858000.0 in 2025, then surged by 31.47% to $1.1 million in 2026.
• Business Quant data shows ARTV's Other Accumulated Expenses at $1.1 million in Q1 2026, $858000.0 in Q4 2025, and $442000.0 in Q3 2025.